Research to Real-World Application: Experts Weigh In on the Underuse of Anticoagulants

Participating Faculty: Research to Real World Application: Experts Weigh In on the Underuse of Anticoagulants

ByJan Berger, MD, MJ,Donald C. Balfour III, MD, FACP,Joseph E. Biskupiak, PhD, MBA,Jeffrey D. Dunn, PharmD, MBA,Dennis B. Liotta, MD, MBA,Geno J. Merli, MD, FACP, FHM, FSVM,Edmund J. Pezalla, MD,

December 26th 2014

Research to Real-World Application: Experts Weigh In on the Underuse of Anticoagulants

ByJan Berger, MD, MJ,Donald C. Balfour III, MD, FACP,Joseph E. Biskupiak, PhD, MBA,Jeffrey D. Dunn, PharmD, MBA,Dennis B. Liotta, MD, MBA,Geno J. Merli, MD, FACP, FHM, FSVM,Edmund J. Pezalla, MD,

December 26th 2014

This article is the first in a 2-part series that summarizes the proceedings from a roundtable meeting that was conducted to discuss real-world considerations in nonvalvular atrial fibrillation and venous thromboembolism.

Research to Real-World Application: Experts Weigh In on the Underuse of Anticoagulants

Participating Faculty: Research to Real World Application: Experts Weigh In on the Underuse of Anticoagulants

Research to Real-World Application: Experts Weigh In on the Underuse of Anticoagulants

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era